1. Home
  2. POR vs RYTM Comparison

POR vs RYTM Comparison

Compare POR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portland General Electric Co

POR

Portland General Electric Co

HOLD

Current Price

$50.62

Market Cap

5.8B

Sector

Utilities

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$88.27

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POR
RYTM
Founded
1889
2008
Country
United States
United States
Employees
2915
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.8B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
POR
RYTM
Price
$50.62
$88.27
Analyst Decision
Hold
Strong Buy
Analyst Count
11
14
Target Price
$48.55
$131.14
AVG Volume (30 Days)
1.2M
475.3K
Earning Date
05-01-2026
05-05-2026
Dividend Yield
4.32%
N/A
EPS Growth
N/A
28.34
EPS
0.38
N/A
Revenue
$3,576,000,000.00
N/A
Revenue This Year
$6.94
$55.34
Revenue Next Year
$5.83
$86.06
P/E Ratio
$133.47
N/A
Revenue Growth
3.95
N/A
52 Week Low
$39.55
$60.71
52 Week High
$54.62
$122.20

Technical Indicators

Market Signals
Indicator
POR
RYTM
Relative Strength Index (RSI) 53.99 50.75
Support Level $50.29 $82.43
Resistance Level $51.43 $92.51
Average True Range (ATR) 1.02 3.73
MACD 0.18 -0.10
Stochastic Oscillator 69.81 51.93

Price Performance

Historical Comparison
POR
RYTM

About POR Portland General Electric Co

Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: